Listed

Cue Biopharma, Inc.

CUENasdaqCIK 1645460HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$7.9m, Q2 FY2026
Operating income−$87.7m, Q2 FY2026
Net income−$153.1m, Q2 FY2026
Cue Biopharma, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m2.1Revenue, Q3 FY2023, three months to 2023-09-30$2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure1.8Revenue, Q4 FY2023, three months to 2023-12-31$1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure1.7Revenue, Q1 FY2024, three months to 2024-03-31$1.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure2.7Revenue, Q2 FY2024, three months to 2024-06-30$2.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure3.3Revenue, Q3 FY2024, three months to 2024-09-30$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure1.6Revenue, Q4 FY2024, three months to 2024-12-31$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure0.4Revenue, Q1 FY2025, three months to 2025-03-31$421.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure3.0Revenue, Q2 FY2025, three months to 2025-06-30$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure2.1Revenue, Q3 FY2025, three months to 2025-09-30$2.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure21.9Revenue, Q4 FY2025, three months to 2025-12-31$21.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure5.7Revenue, Q1 FY2026, three months to 2026-03-31$5.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure7.9Revenue, Q2 FY2026, three months to 2026-06-30$7.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Research and development$m9.9Research and development, Q3 FY2023, three months to 2023-09-30$9.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure10.9Research and development, Q4 FY2023, three months to 2023-12-31$10.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure10.2Research and development, Q1 FY2024, three months to 2024-03-31$10.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure9.5Research and development, Q2 FY2024, three months to 2024-06-30$9.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure9.4Research and development, Q3 FY2024, three months to 2024-09-30$9.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure7.2Research and development, Q4 FY2024, three months to 2024-12-31$7.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure8.5Research and development, Q1 FY2025, three months to 2025-03-31$8.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure7.9Research and development, Q2 FY2025, three months to 2025-06-30$7.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure4.8Research and development, Q3 FY2025, three months to 2025-09-30$4.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure16.5Research and development, Q4 FY2025, three months to 2025-12-31$16.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure6.9Research and development, Q1 FY2026, three months to 2026-03-31$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure49.0Research and development, Q2 FY2026, three months to 2026-06-30$49.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Operating income$m(11.4)Operating income, Q3 FY2023, three months to 2023-09-30−$11.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure(13.8)Operating income, Q4 FY2023, three months to 2023-12-31−$13.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure(12.7)Operating income, Q1 FY2024, three months to 2024-03-31−$12.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure(10.4)Operating income, Q2 FY2024, three months to 2024-06-30−$10.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure(8.8)Operating income, Q3 FY2024, three months to 2024-09-30−$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure(9.6)Operating income, Q4 FY2024, three months to 2024-12-31−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure(12.3)Operating income, Q1 FY2025, three months to 2025-03-31−$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(8.6)Operating income, Q2 FY2025, three months to 2025-06-30−$8.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure(7.6)Operating income, Q3 FY2025, three months to 2025-09-30−$7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure2.0Operating income, Q4 FY2025, three months to 2025-12-31$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure(5.4)Operating income, Q1 FY2026, three months to 2026-03-31−$5.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(87.7)Operating income, Q2 FY2026, three months to 2026-06-30−$87.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Interest expense$m0.3Interest expense, Q3 FY2023, three months to 2023-09-30$254.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure(0.7)Interest expense, Q4 FY2023, three months to 2023-12-31−$748.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2024, three months to 2024-03-31$33.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figurenot reportednot reportednot reported0.1Interest expense, Q1 FY2025, three months to 2025-03-31$100.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$33.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figurenot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(11.0)Net income, Q3 FY2023, three months to 2023-09-30−$11.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure(13.4)Net income, Q4 FY2023, three months to 2023-12-31−$13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure(12.3)Net income, Q1 FY2024, three months to 2024-03-31−$12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure(10.2)Net income, Q2 FY2024, three months to 2024-06-30−$10.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure(8.7)Net income, Q3 FY2024, three months to 2024-09-30−$8.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure(9.5)Net income, Q4 FY2024, three months to 2024-12-31−$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure(12.3)Net income, Q1 FY2025, three months to 2025-03-31−$12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(8.5)Net income, Q2 FY2025, three months to 2025-06-30−$8.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure(7.4)Net income, Q3 FY2025, three months to 2025-09-30−$7.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure1.6Net income, Q4 FY2025, three months to 2025-12-31$1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure(5.2)Net income, Q1 FY2026, three months to 2026-03-31−$5.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(153)Net income, Q2 FY2026, three months to 2026-06-30−$153.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Diluted EPS$ per share(0.24)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figurenot reported(0.25)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure(0.20)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure(0.17)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figurenot reported(4.95)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$4.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(2.67)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$2.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figurenot reported(1.08)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(24.14)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$24.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Basic EPS$ per share(0.24)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figurenot reported(0.25)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure(0.20)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure(0.17)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figurenot reported(4.95)Basic EPS, Q1 FY2025, three months to 2025-03-31−$4.95 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(2.67)Basic EPS, Q2 FY2025, three months to 2025-06-30−$2.67 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure(0.07)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figurenot reported(1.08)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(24.14)Basic EPS, Q2 FY2026, three months to 2026-06-30−$24.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure

Balance sheet

Cash and equivalents$17.4m, Q2 FY2026
Long-term debt$0, FY2024
Shareholders' equity$2.3m, Q2 FY2026
Cue Biopharma, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m54.7Cash and equivalents, Q3 FY2023, at 2023-09-30$54.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure48.5Cash and equivalents, FY2023, at 2023-12-31$48.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure41.0Cash and equivalents, Q1 FY2024, at 2024-03-31$41.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure30.0Cash and equivalents, Q2 FY2024, at 2024-06-30$30.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure32.4Cash and equivalents, Q3 FY2024, at 2024-09-30$32.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure22.5Cash and equivalents, FY2024, at 2024-12-31$22.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-16, accession 0001193125-26-108287.Report this figure13.1Cash and equivalents, Q1 FY2025, at 2025-03-31$13.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure27.5Cash and equivalents, Q2 FY2025, at 2025-06-30$27.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure11.7Cash and equivalents, Q3 FY2025, at 2025-09-30$11.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure27.1Cash and equivalents, FY2025, at 2025-12-31$27.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure16.4Cash and equivalents, Q1 FY2026, at 2026-03-31$16.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure17.4Cash and equivalents, Q2 FY2026, at 2026-06-30$17.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Current assets$m57.5Current assets, Q3 FY2023, at 2023-09-30$57.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure51.5Current assets, FY2023, at 2023-12-31$51.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure44.7Current assets, Q1 FY2024, at 2024-03-31$44.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure33.9Current assets, Q2 FY2024, at 2024-06-30$33.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure37.3Current assets, Q3 FY2024, at 2024-09-30$37.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure25.1Current assets, FY2024, at 2024-12-31$25.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-16, accession 0001193125-26-108287.Report this figure15.9Current assets, Q1 FY2025, at 2025-03-31$15.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure30.8Current assets, Q2 FY2025, at 2025-06-30$30.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure25.8Current assets, Q3 FY2025, at 2025-09-30$25.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure37.0Current assets, FY2025, at 2025-12-31$37.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure26.4Current assets, Q1 FY2026, at 2026-03-31$26.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure26.6Current assets, Q2 FY2026, at 2026-06-30$26.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Total assets$m68.9Total assets, Q3 FY2023, at 2023-09-30$68.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure61.5Total assets, FY2023, at 2023-12-31$61.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure54.0Total assets, Q1 FY2024, at 2024-03-31$54.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure42.3Total assets, Q2 FY2024, at 2024-06-30$42.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure44.8Total assets, Q3 FY2024, at 2024-09-30$44.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure32.2Total assets, FY2024, at 2024-12-31$32.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-16, accession 0001193125-26-108287.Report this figure22.3Total assets, Q1 FY2025, at 2025-03-31$22.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure40.7Total assets, Q2 FY2025, at 2025-06-30$40.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure31.6Total assets, Q3 FY2025, at 2025-09-30$31.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure42.2Total assets, FY2025, at 2025-12-31$42.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure30.9Total assets, Q1 FY2026, at 2026-03-31$30.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure30.7Total assets, Q2 FY2026, at 2026-06-30$30.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Current liabilities$m17.2Current liabilities, Q3 FY2023, at 2023-09-30$17.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure17.1Current liabilities, FY2023, at 2023-12-31$17.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure18.1Current liabilities, Q1 FY2024, at 2024-03-31$18.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure16.5Current liabilities, Q2 FY2024, at 2024-06-30$16.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure16.8Current liabilities, Q3 FY2024, at 2024-09-30$16.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure13.7Current liabilities, FY2024, at 2024-12-31$13.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-16, accession 0001193125-26-108287.Report this figure15.5Current liabilities, Q1 FY2025, at 2025-03-31$15.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure19.3Current liabilities, Q2 FY2025, at 2025-06-30$19.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure15.5Current liabilities, Q3 FY2025, at 2025-09-30$15.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure13.5Current liabilities, FY2025, at 2025-12-31$13.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure7.4Current liabilities, Q1 FY2026, at 2026-03-31$7.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure21.2Current liabilities, Q2 FY2026, at 2026-06-30$21.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Total liabilities$m26.2Total liabilities, Q3 FY2023, at 2023-09-30$26.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure24.4Total liabilities, FY2023, at 2023-12-31$24.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure23.9Total liabilities, Q1 FY2024, at 2024-03-31$23.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure20.7Total liabilities, Q2 FY2024, at 2024-06-30$20.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure19.4Total liabilities, Q3 FY2024, at 2024-09-30$19.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure14.7Total liabilities, FY2024, at 2024-12-31$14.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-16, accession 0001193125-26-108287.Report this figure15.7Total liabilities, Q1 FY2025, at 2025-03-31$15.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure22.5Total liabilities, Q2 FY2025, at 2025-06-30$22.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure18.4Total liabilities, Q3 FY2025, at 2025-09-30$18.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure15.8Total liabilities, FY2025, at 2025-12-31$15.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure9.3Total liabilities, Q1 FY2026, at 2026-03-31$9.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure28.4Total liabilities, Q2 FY2026, at 2026-06-30$28.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure
Long-term debt$m5.2Long-term debt, Q3 FY2023, at 2023-09-30$5.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure4.2Long-term debt, FY2023, at 2023-12-31$4.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure3.2Long-term debt, Q1 FY2024, at 2024-03-31$3.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure2.3Long-term debt, Q2 FY2024, at 2024-06-30$2.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure1.3Long-term debt, Q3 FY2024, at 2024-09-30$1.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure0.0Long-term debt, FY2024, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$m4.0Current portion of debt, Q3 FY2023, at 2023-09-30$4.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure4.0Current portion of debt, FY2023, at 2023-12-31$4.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2024-03-28, accession 0000950170-24-038059.Report this figure4.0Current portion of debt, Q1 FY2024, at 2024-03-31$4.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure4.0Current portion of debt, Q2 FY2024, at 2024-06-30$4.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure4.0Current portion of debt, Q3 FY2024, at 2024-09-30$4.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reported0.0Short-term borrowings, FY2023, at 2023-12-31$37.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2024-03-28, accession 0000950170-24-038059.Report this figure0.0Short-term borrowings, Q1 FY2024, at 2024-03-31$37.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figurenot reportednot reported0.0Short-term borrowings, FY2024, at 2024-12-31$37.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2025-03-31, accession 0000950170-25-047677.Report this figure0.1Short-term borrowings, Q1 FY2025, at 2025-03-31$100.0k. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figurenot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m42.7Shareholders' equity, Q3 FY2023, at 2023-09-30$42.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure37.1Shareholders' equity, FY2023, at 2023-12-31$37.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-16, accession 0001193125-26-108287.Report this figure30.0Shareholders' equity, Q1 FY2024, at 2024-03-31$30.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure21.6Shareholders' equity, Q2 FY2024, at 2024-06-30$21.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure25.4Shareholders' equity, Q3 FY2024, at 2024-09-30$25.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure17.5Shareholders' equity, FY2024, at 2024-12-31$17.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure6.6Shareholders' equity, Q1 FY2025, at 2025-03-31$6.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure18.2Shareholders' equity, Q2 FY2025, at 2025-06-30$18.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure13.2Shareholders' equity, Q3 FY2025, at 2025-09-30$13.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure26.4Shareholders' equity, FY2025, at 2025-12-31$26.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure21.6Shareholders' equity, Q1 FY2026, at 2026-03-31$21.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure2.3Shareholders' equity, Q2 FY2026, at 2026-06-30$2.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure

Cash flow

Operating cash flow−$29.0m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Share repurchases$0, Q4 FY2023
Cue Biopharma, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(7.8)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$7.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0000950170-24-127005. Derived: 9-month figure less the 6-month figure.Report this figure(11.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure(9.8)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$9.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure(10.0)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0000950170-25-107270. Derived: 6-month figure less the 3-month figure.Report this figure(7.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277466. Derived: 9-month figure less the 6-month figure.Report this figure(9.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$9.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure(8.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(3.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-352128. Derived: 6-month figure less the 3-month figure.Report this figure(9.0)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$9.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277466. Derived: 9-month figure less the 6-month figure.Report this figure(1.1)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure(10.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure(29.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$29.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-352128. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0000950170-24-127005. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0000950170-25-047677. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$55.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$10.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0000950170-25-107270. Derived: 6-month figure less the 3-month figure.Report this figure(0.0)Capital expenditure, Q3 FY2024, three months to 2024-09-30−$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277466. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2025, three months to 2025-03-31$150.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$27.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001193125-26-352128. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277466. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108287. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$121.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001193125-26-352128. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$m0.0Share repurchases, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2023-11-03, accession 0000950170-23-058838. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2024-03-28, accession 0000950170-24-038059. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)6.34m, Q2 FY2026
Cue Biopharma, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares35.4Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3035,383,430 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-03, accession 0000950170-23-058838.Report this figure44.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3144,652,353 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-056838.Report this figure44.8Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3044,798,760 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-14, accession 0000950170-24-096967.Report this figure46.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3046,358,555 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0000950170-24-127005.Report this figure49.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3149,466,711 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-069125.Report this figure50.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3050,174,756 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0000950170-25-107270.Report this figure51.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3051,229,701 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure2.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-312,475,156 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure3.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-303,181,980 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure101Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30100,869,349 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277466.Report this figure4.8Diluted shares (weighted), Q1 FY2026, three months to 2026-03-314,807,494 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001193125-26-224091.Report this figure6.3Diluted shares (weighted), Q2 FY2026, three months to 2026-06-306,340,844 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure

Shares outstanding: 7.26mShares outstanding, period not labelled, at 2026-08-127,264,414 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-352128.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.